Research Report: MRK

Analysis Date: 2025-12-07T16:37:06.150582 Trading Period: 2025-12-08 to 2025-12-19

Company Overview

Company: Merck & Co., Inc. Sector: Healthcare | Industry: Drug Manufacturers - General Current Price: $99.72 Market Cap: $249,078,956,032 Beta: 0.30 Avg Volume: 13,187,250 P/E Ratio: 13.19 Website: https://www.merck.com

Description: Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as liv...

Trading Recommendation

Action: STRONG AVOID Confidence: 20.0/100 Position Size: 0.0% of portfolio

Rationale: Unfavorable conditions (composite: 29.8/100, risk: EXTREME, red flags: 1).

Screening Status

Passed Filters: ✓ Yes Notes: Passed all screening filters

Quantitative Analysis

Composite Score: 3.20/5.0 Percentile Rank: 100%

Factor Scores:

Technical Analysis

Setup Score: 1/8 Setup Notes: In uptrend

Price Levels:

Momentum & Volume:

Risk Assessment

Risk Level: EXTREME Confidence: 10.0/100 Total Red Flags: 1 Earnings Risk: No

Critical Issues:


This report is generated by PM automated research system. Always perform your own due diligence before trading.